Locations
South San Francisco, CA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series A
founded in
2023
Shinobi Therapeutics is pioneering immune evasive iPS cell therapies that work with the immune system to treat solid tumors and other diseases. Utilizing their innovative Katana platform, they offer CD8αβ iPS-T cell therapies that are designed to be off-the-shelf, cost-effective, and capable of durable patient responses through re-dosing. Their technology addresses the challenges of tumor heterogeneity and aims to make advanced cell therapies accessible to a global patient population. With a strong foundation in immune evasion technology and a team of industry leaders, Shinobi is positioned to revolutionize cancer treatment and expand into other therapeutic areas.
Something looks off?